Been with the company since pre-problems, took the chance/risks and held out and grew, the price offered is not worthy of the potential in this company. I will vote NO, and prefer to stay for the long run. The world environment is changing and this company is in a needed niche space and much potential for growth.
NO ... lets not fall for ultimatums ... scare mongering **This is the last chance offer** laughable, nothing to lose and MUCH to gain in the long run. To the directors if they can't do better they should move on.
- Forums
- ASX - By Stock
- MRM
- Ann: Cyan Increases Scheme Consideration to $2.70 per share
Ann: Cyan Increases Scheme Consideration to $2.70 per share, page-13
Featured News
Add MRM (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online